CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
500 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
(±)-Enitociclib
CAS :<p>(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.</p>Formule :C19H18F2N4O2SDegré de pureté :99.29%Couleur et forme :SolidMasse moléculaire :404.43Garcinone C
CAS :<p>Garcinone C, a xanthone from Garcinia oblongifolia, is anti-inflammatory, promotes healing, and may fight some cancers.</p>Formule :C23H26O7Degré de pureté :99.13% - 99.92%Couleur et forme :SolidMasse moléculaire :414.45Nimbolide
CAS :<p>Nimbolide, from neem, inhibits CDK4/6, NF-κB, Wnt, PI3K-Akt, MAPK, JAK-STAT pathways and induces apoptosis.</p>Formule :C27H30O7Degré de pureté :95.84% - 99.4%Couleur et forme :SolidMasse moléculaire :466.52Amantadine hydrochloride
CAS :<p>Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.</p>Formule :C10H18ClNDegré de pureté :99.98%Couleur et forme :Solid CrystallineMasse moléculaire :187.71Simurosertib
CAS :<p>Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).</p>Formule :C17H19N5OSDegré de pureté :99.93% - 99.93%Couleur et forme :SolidMasse moléculaire :341.43CDK4/6-IN-2
CAS :<p>CDK4/6-IN-2 是一种CDK4和CDK6抑制剂，IC50分别为 2.7 和 16 nM。</p>Formule :C27H32F2N8Degré de pureté :99.47%Couleur et forme :SolidMasse moléculaire :506.59hSMG-1 inhibitor 11j
CAS :<p>hSMG-1 inhibitor 11j: pyrimidine, IC50=0.11 nM, >455x selective vs. mTOR/PI3Kα/γ/CDK1/CDK2; cancer research use.</p>Formule :C27H28ClN7O3SDegré de pureté :99.22% - 99.65%Couleur et forme :SolidMasse moléculaire :566.07BRD6989
CAS :<p>BRD6989, a cortistatin A analog, inhibits CDK8/19, enhances IL-10, and binds CDK8 with a 200 nM IC50.</p>Formule :C16H16N4Degré de pureté :99.43%Couleur et forme :SolidMasse moléculaire :264.33Avotaciclib
CAS :<p>Avotaciclib (BEY1107) is a potent and orally active cyclin dependent kinase 1 (CDK1) inhibitor.Avotaciclib can be used to study locally advanced or metastatic</p>Formule :C13H11N7ODegré de pureté :98.02%Couleur et forme :SolidMasse moléculaire :281.27CDKI-73
CAS :<p>CDKI-73: strong CDK9 blocker, Ki 4 nM, kills CLL cells selectively, aids cisplatin.</p>Formule :C15H15FN6O2S2Degré de pureté :98.11%Couleur et forme :SolidMasse moléculaire :394.45Lerociclib dihydrochloride
CAS :<p>Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/</p>Formule :C26H36Cl2N8ODegré de pureté :97.4%Couleur et forme :SolidMasse moléculaire :547.52Ca2+ channel agonist 1
CAS :<p>Ca2+ channel agonist 1 activates N-type Ca2+ channels and inhibits Cdk2 (EC50: 14.23 μM/3.34 μM) for motor nerve issues.</p>Formule :C19H26N6ODegré de pureté :97.71%Couleur et forme :SolidMasse moléculaire :354.45Cirtuvivint
CAS :<p>Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor that can be used to study arthritis.</p>Formule :C24H25N7ODegré de pureté :99.46% - >99.99%Couleur et forme :SolidMasse moléculaire :427.5XPW1
CAS :<p>XPW1 is a CDK9 inhibitor with antitumor activity, inhibits DNA repair procedures, and can be used for the research of clear cell renal cell carcinoma.</p>Formule :C36H39ClFN7O2Degré de pureté :98.08%Couleur et forme :SoildMasse moléculaire :656.19MBQ-167
CAS :<p>MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).</p>Formule :C22H18N4Degré de pureté :98.07% - 99.52%Couleur et forme :SolidMasse moléculaire :338.41Cyclin K degrader 1
<p>Cyclin K degrader 1 is a Cyclin K degrader.Cyclin K degrader 1 is a degrader converted from AT-7519.Cyclin K degrader 1 has weak degrading activity against Cyclin K but does not result in a sustained decrease in degradation affinity.Cyclin K degrader 1 is a degrader converted from AT-7519.</p>Formule :C23H17Cl2N5O2Degré de pureté :99.76%Couleur et forme :SolidMasse moléculaire :466.32NU6140
CAS :<p>NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM).</p>Formule :C23H30N6O2Degré de pureté :98.33%Couleur et forme :SolidMasse moléculaire :422.52NVP-2
CAS :<p>NVP-2 selectively inhibits CDK9 (IC50: 0.514 nM), prompts apoptosis, and affects other CDKs (IC50: 0.584-0.706 μM).</p>Formule :C27H37ClN6O2Degré de pureté :99.13%Couleur et forme :SolidMasse moléculaire :513.07Ribociclib succinate
CAS :<p>Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).</p>Formule :C27H36N8O5Degré de pureté :99.9%Couleur et forme :SolidMasse moléculaire :552.63(R)-CR8
CAS :<p>(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.</p>Formule :C24H29N7ODegré de pureté :98.41%Couleur et forme :SolidMasse moléculaire :431.53Trilaciclib hydrochloride
CAS :<p>Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).</p>Formule :C24H32Cl2N8ODegré de pureté :99.69% - 99.89%Couleur et forme :SolidMasse moléculaire :519.47CDK2-IN-4
CAS :<p>CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A.</p>Formule :C23H18N6O2SDegré de pureté :97.24% - 99.10%Couleur et forme :SolidMasse moléculaire :442.49Samuraciclib hydrochloride
CAS :<p>Samuraciclib HCl is an oral CDK7 inhibitor (IC50: 41 nM), 45-230x selective over CDK1/2/5/9, inhibiting breast cancer growth (GI50: 0.2-0.3 μM).</p>Formule :C22H31ClN6ODegré de pureté :98.99% - 99.8%Couleur et forme :SolidMasse moléculaire :430.97Cdk2/Cyclin Inhibitory Peptide II
CAS :<p>Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].</p>Formule :C110H200N48O25Couleur et forme :SolidMasse moléculaire :2595.07CDK2-IN-7
CAS :<p>CDK2-IN-7 is a CDK2 inhibitor for treating cancer ( IC 50 < 50 nM).</p>Formule :C24H30N6O4SCouleur et forme :SolidMasse moléculaire :498.6PP-C8
<p>PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.</p>Formule :C43H51FN12O7Couleur et forme :SolidMasse moléculaire :866.94SNX7
CAS :<p>SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.</p>Formule :C15H14N2ODegré de pureté :99.05%Couleur et forme :SolidMasse moléculaire :238.28CDK12-IN-6
CAS :<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Formule :C20H21F2N9Couleur et forme :SolidMasse moléculaire :425.448CDK4/6-IN-23
<p>CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.</p>Formule :C32H34FN7O4Couleur et forme :SolidMasse moléculaire :599.655FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Couleur et forme :LiquidCAF-382
<p>CAF-382 (compound B1), an analog of SNS-032, functions as a CDKL5 and pan-CDK inhibitor, exhibiting modest inhibitory activity against GSK3α/β with an affinity</p>Formule :C16H22N4O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :366.5CDK9 inhibitor HH1
CAS :<p>CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.</p>Formule :C13H15N3OSDegré de pureté :99.92%Couleur et forme :SolidMasse moléculaire :261.34TMX-2138
CAS :<p>TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.</p>Formule :C40H43BrFN9O11SCouleur et forme :SolidMasse moléculaire :956.791CDK-IN-15
CAS :<p>CDK-IN-15 (Compound 456) is an effective inhibitor of Cyclin A, exhibiting an IC50 value of 0.14 μM.</p>Formule :C45H63Cl2F4N7O8Couleur et forme :SolidMasse moléculaire :976.92Anticancer agent 264
<p>Anticanceragent 264 (Compound 5w) is an anticancer compound that exhibits significant antiproliferative activity in tumor cell lines, with an IC50 range of 7.5-33.67 μM. It notably induces cell cycle arrest at the G2/M phase in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. This compound reduces key cell cycle proteins CDK1, CDK2, and Cyclin B1 in a dose-dependent manner and has strong binding activity with differentiation inhibitors and DNA-binding proteins. Anticanceragent 264 is useful for research in the cancer disease domain.</p>Formule :C23H18ClF5N6OCouleur et forme :SolidMasse moléculaire :524.87PROTAC FLT3/CDKs degrader-1
<p>PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.</p>Formule :C40H42N12O5Masse moléculaire :770.34011Olomoucine
CAS :<p>Olomoucine hinders Cdk2, Cdc2, CDK5, ERK1, regulates the cell cycle, and fights melanoma; IC50s: 3-25 µM.</p>Formule :C15H18N6ODegré de pureté :99.77%Couleur et forme :White Crystalline PowderMasse moléculaire :298.34Cell Cycle Compound Library
<p>A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);</p>Couleur et forme :Odour SolidPROTAC CDK9 degrader-8
<p>PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].</p>Formule :C44H52Cl2N10O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :903.85PROTAC CDK9 degrader-7
CAS :<p>PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (</p>Formule :C43H50Cl2N8O9Couleur et forme :SoildMasse moléculaire :893.81AM5992
CAS :<p>AM5992 (example 195) is a potent CDK4 and CDK6 inhibitor (CDK4, IC50= 0.013 μM). AM5992 can be used for the research of CDK4-mediated disorders.</p>Formule :C27H33FN8ODegré de pureté :98%Couleur et forme :SoildMasse moléculaire :504.6[Ala92]-p16 (84-103)
CAS :<p>Peptide derived from the tumor suppressor protein p16; inhibits cyclin-dependent kinase-4 (cdk4)/cyclin D1 (IC50 ~ 1.5 μM) and binds to cdk6.</p>Formule :C93H155N31O26Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2123.44CDK7-IN-21
CAS :<p>CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor [1] .</p>Formule :C33H36FN9O2Couleur et forme :SolidMasse moléculaire :609.7XY028-133
CAS :<p>XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.</p>Formule :C53H67N11O7SDegré de pureté :97.11%Couleur et forme :SolidMasse moléculaire :1002.23EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Formule :C30H20N6OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :512.58JHD205
<p>JHD205 is an inhibitor of CDK4/6.</p>Formule :C32H40F2N8OCouleur et forme :SolidMasse moléculaire :590.71CDK9-IN-25
<p>CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.</p>Formule :C15H16FN5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :285.32Cimpuciclib
CAS :<p>Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.</p>Formule :C30H35FN8OCouleur et forme :SolidMasse moléculaire :542.663[pThr3]-CDK5 Substrate
CAS :<p>[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM[1].</p>Formule :C53H100N15O15PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1218.43CDK4/6-IN-11
CAS :<p>CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.</p>Formule :C43H49N11O7Couleur et forme :SolidMasse moléculaire :831.92dCeMM3
CAS :<p>dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.</p>Formule :C14H11ClN4OSDegré de pureté :98.48% - 99.41%Couleur et forme :SolidMasse moléculaire :318.78CP-07
<p>CP-07 is a selective and effective PROTAC CDK9 degrader (DC50: 43 nM), demonstrating inhibition of 22RV1 cell proliferation (IC50: 62 nM) and colony formation</p>Formule :C45H48N6O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :800.9CDK2-IN-19
<p>CDK2-IN-19 (Compound 32) is a selective, orally active inhibitor of CDK2 (K i: 0.18 nM) that exhibits anticancer activity in mice with OVCAR3 tumors [1].</p>Formule :C20H21FN6O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :460.48HTH-01-091 TFA
<p>HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.</p>Formule :C28H29Cl2F3N4O4Couleur et forme :SolidMasse moléculaire :613.46(E/Z)-THZ1 2HCl
CAS :<p>THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.</p>Formule :C31H30Cl3N7O2Degré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :638.98CDK9-IN-35
<p>CDK9-IN-35 (compound 10j) acts as an inhibitor of CDK9/CyclinT1, exhibiting an IC50 of 10.2 nM. It also shows an IC50 of 20 nM against the HCT-116 cell line.</p>Formule :C26H24ClFN4O4SCouleur et forme :SolidMasse moléculaire :543.01CDK2/PIM1-IN-1
<p>CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.</p>Couleur et forme :Odour SolidMeBIO
CAS :<p>MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.</p>Formule :C17H12BrN3O2Degré de pureté :99.64%Couleur et forme :SolidMasse moléculaire :370.2CDK7-IN-6
CAS :<p>CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.</p>Formule :C26H34ClN9OCouleur et forme :SolidMasse moléculaire :524.07[pSer2, pSer5, pSer7]-CTD TFA
<p>Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.</p>Formule :C98H138F3N21O39Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2291.25LL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Formule :C37H43N5OCouleur et forme :SolidMasse moléculaire :573.77Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Couleur et forme :Odour SolidCdk2/Cyclin Inhibitory Peptide I
<p>CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.</p>Formule :C111H196N48O23Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2571.05Maleimide-PEG8-Val-Ala-PAB-SNS032
<p>Maleimide-Val-Ala-PAB-SNS032 is a conjugated compound used as an ADC toxin and linker. SNS032 acts as a CDK inhibitor, reducing cancer cell viability and arresting the cell cycle at the G1/S phase. Maleimide-Val-Ala-PAB functions as a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 is utilized in the synthesis of ADC molecules.</p>Formule :C59H87N9O18S2Masse moléculaire :1273.56105Men 10376
CAS :<p>Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.</p>Formule :C57H68N12O10Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1081.22JWZ-5-13
<p>JWZ-5-13 is an effective CDK7 PROTAC degrader that significantly degrades CDK7 via the ubiquitin-proteasome system. JWZ-5-13 also exhibits antitumor activity.</p>Formule :C54H66N10O6SMasse moléculaire :982.48875Eciruciclib
CAS :<p>Eciruciclib is an inhibitor of CDK with antitumor properties.</p>Formule :C27H33FN8Degré de pureté :99.73%Couleur et forme :SolidMasse moléculaire :488.6CPS2
CAS :<p>CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.</p>Formule :C38H42N12O10S2Couleur et forme :SolidMasse moléculaire :890.94JH-XVI-178
CAS :<p>JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.</p>Formule :C22H22ClN7OCouleur et forme :SolidMasse moléculaire :435.92SHR5428
<p>SHR5428 is an orally active, selective, noncovalent inhibitor of CDK7, displaying potent enzymatic inhibition (IC50 = 2.3 nM) and effectively suppressing</p>Degré de pureté :98%Couleur et forme :Odour SolidJH-XI-10-02
CAS :<p>JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.</p>Formule :C53H69N5O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :920.161CDK7-IN-5
CAS :<p>CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).</p>Formule :C34H45N9O2Couleur et forme :SolidMasse moléculaire :611.795CDK2-IN-20
<p>CDK2-IN-20 (compound 3b), a CDK2 inhibitor, exhibits cytotoxic effects on tumor cells with an IC50 ranging from 5.52-17.09 µM.</p>Degré de pureté :98%Couleur et forme :Odour SolidBSJ-03-204
CAS :<p>BSJ-03-204 is a selective Cdk4/6 degrader.</p>Formule :C43H48N10O8Couleur et forme :SolidMasse moléculaire :832.9CDK9 degrader-1
<p>CDK9degrader-1 is a selective CDK9 degrader (DC50: 0.4073 µM). It recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuse with lysosomes to degrade CDK9 and its partner protein, Cyclin T1 (DC50: 1.215 µM). CDK9degrader-1 induces caspase 3-mediated apoptosis and exhibits antitumor activity in a mouse HCT116 xenograft model.</p>Formule :C32H34Cl2N6O4Couleur et forme :SolidMasse moléculaire :637.56PROTAC CDK9 degrader-2
CAS :<p>PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.</p>Formule :C39H36N6O10Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :748.74BSJ-5-63
CAS :<p>BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research.</p>Formule :C52H74ClN9O6S2Couleur et forme :SolidMasse moléculaire :1020.78PROTAC CDK9/CycT1 Degrader-2
<p>PROTAC CDK9/CycT1 Degrader-2 inhibits CDK9 with an IC50 of 45 nM [1].</p>Formule :C30H36N4O6S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :612.76CDK4/6-IN-5
CAS :<p>CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)</p>Formule :C22H28ClFN6O4SCouleur et forme :SolidMasse moléculaire :527.01CDK7-IN-1
CAS :<p>CDK7-IN-1, analog of YKL-5-124, inhibits cdk7 with IC50 < 100 nM.</p>Formule :C28H35N7O3Couleur et forme :SolidMasse moléculaire :517.634ZNL-05-044
<p>ZNL-05-044, a CDK11 inhibitor, exhibits IC50 values of 0.23 μM for CDK11A and 0.27 μM for CDK11B, as determined by NanoBRET assay.</p>Formule :C21H22Cl2N6OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :477.41CDK9-IN-27
<p>CDK9-IN-27 (Compound 6a), a CDK9 inhibitor with an IC50 of 0.424 μM, induces apoptosis and S-phase cell cycle arrest.</p>Formule :C23H18ClN5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :447.87CDK2/Bcl2-IN-1
<p>CDK2/Bcl2-IN-1 (compound 1) is a saponin-based inhibitor of CDK-2 (IC50=117.6 nM) that exhibits potent cytotoxic effects on cancer cells.</p>Formule :C35H56O10SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :668.88(R)-Enitociclib
CAS :<p>(R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.</p>Formule :C19H18F2N4O2SDegré de pureté :98.98%Couleur et forme :SoildMasse moléculaire :404.43CDK2-IN-43
<p>CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.</p>Formule :C19H27N7OCouleur et forme :SolidMasse moléculaire :369.464YKL-5-124 TFA
CAS :<p>YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.</p>Formule :C30H34F3N7O5Couleur et forme :SolidMasse moléculaire :629.63bio-THZ1
CAS :<p>bio-THZ1 is a biotinylated version of THZ1. THZ1 is a selective and irreversibly covalent CDK7 inhibitor (IC50: 3.2 nM).</p>Formule :C52H65ClN12O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1053.673-Methylthienyl-carbonyl-JNJ-7706621
CAS :<p>Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.</p>Formule :C14H14N6O3S2Couleur et forme :SolidMasse moléculaire :378.43CDK8/19-IN-3
<p>CDK8/19-IN-3 (compound 3-7) is a potent and selective inhibitor of CDK8 and CDK19. It can increase IL-10 levels and has potential for research in inflammatory bowel disease (IBD).</p>Formule :C20H23FN6O2Couleur et forme :SolidMasse moléculaire :398.434BLINK15
<p>BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.</p>Couleur et forme :Odour SolidPROTAC CDK9 degrader-11
CAS :<p>PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)</p>Formule :C39H48Cl2N10O5Couleur et forme :SolidMasse moléculaire :807.768CDK5-IN-1
CAS :<p>CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.</p>Formule :C24H25FN6O3SCouleur et forme :SolidMasse moléculaire :496.56NecroIr2
<p>NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.</p>Formule :C46H30ClIrN6O2Couleur et forme :SolidMasse moléculaire :926.44Abemaciclib metabolite M18
CAS :<p>Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.</p>Formule :C25H28F2N8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :494.54CDK9/EZH2-IN-1
CAS :<p>CDK9/EZH2-IN-1 is a dual-target inhibitor of CDK9 and EZH2 with IC50 values of 83.9 nM and 108.6 nM, respectively. It induces apoptosis and causes DNA double-strand breaks (DSB). Additionally, CDK9/EZH2-IN-1 inhibits the proliferation of MKN45, MDA-MB-453, and SW620 cancer cells, with respective IC50 values of 136.3 nM, 171.3 nM, and 315.7 nM.</p>Formule :C47H59N11O4S2Couleur et forme :SolidMasse moléculaire :906.17CDK2 degrader 3
CAS :<p>CDK2 degrader3 selectively degrades CDK2 and exhibits antitumor activity.</p>Formule :C44H53ClN10O6SCouleur et forme :SolidMasse moléculaire :885.47LSN3106729 hydrochloride
CAS :<p>LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.</p>Formule :C25H29ClF2N8OCouleur et forme :SoildMasse moléculaire :531.00CDK9 ligand 3
CAS :<p>CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.</p>Formule :C18H18BrCl2N5O3Couleur et forme :SolidMasse moléculaire :503.177HS-243
CAS :<p>HS-243 is an inhibitor of IRAK-4 and IRAK-1 with IC50s of 20 and 24 nM. HS-243 shows anti-inflammatory and anticancer activity.</p>Formule :C17H16N4O3Degré de pureté :98.62%Couleur et forme :SolidMasse moléculaire :324.33CDK9-IN-28
<p>PROTAC CDK9/CycT1 Degrader-1 (compounds 10), a potent CDK9 inhibitor, serves as a target protein ligand for PROTAC synthesis.</p>Formule :C32H40N4O6S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :640.81PROTAC CDK9 degrader-6
CAS :<p>PROTAC CDK9 degrader-6 targets and degrades CDK9 isoforms via proteasome, with DC50 of 0.10μM and 0.14μM.</p>Formule :C42H49Cl2N9O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :878.8CDK12/13-IN-2
<p>CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.</p>Formule :C24H22FN7O2Couleur et forme :SolidMasse moléculaire :459.48PF07104091
CAS :<p>PF07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation. Cost-effective and quality-assured.</p>Formule :C19H28N6O4Degré de pureté :99.49%Couleur et forme :SolidMasse moléculaire :404.46TMX-2039
CAS :<p>TMX-2039 is a pan-CDK inhibitor that targets cell cycle CDKs (CDK1, CDK2, CDK4, CDK5, and CDK6) and transcription CDKs (CDK7 and CDK9), with IC50 values of 2.6, 1.0, 52.1, 0.5, 35.0, 32.5, and 25 nM, respectively. It serves as a ligand for the target protein in PROTAC applications.</p>Formule :C17H20BrFN6O3SCouleur et forme :SolidMasse moléculaire :487.347NecroIr1
<p>NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.</p>Formule :C40H29ClIrN5OCouleur et forme :SolidMasse moléculaire :823.36CDK8-IN-12
CAS :<p>CDK8-IN-12: selective CDK8 inhibitor (Ki 14 nM), oral anticancer, blocks GSK-3α/β, PCK-θ, halts MV4-11 cell growth.</p>Formule :C21H20ClN3O2Degré de pureté :99.46% - 99.83%Couleur et forme :SoildMasse moléculaire :381.86A-130A
CAS :<p>A-130A is a polycyclic polyether compound belonging to the nigericin group of antibiotics generated by Streptomyces hygroscopicus strain.</p>Formule :C47H78O13Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :851.11CDK7-IN-7
CAS :<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Formule :C20H20BrF3N6O2Couleur et forme :SolidMasse moléculaire :513.319Roccellic Acid
CAS :<p>Roccellic acid from R. montagnei lichen has antibacterial, anticancer properties; MIC 46.9 μg/ml; inhibits cancer cells by up to 87.9%.</p>Formule :C17H32O4Couleur et forme :SolidMasse moléculaire :300.43CDK12-IN-4
CAS :<p>CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).</p>Formule :C20H20F2N8OCouleur et forme :SolidMasse moléculaire :426.432IV-361
CAS :<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Formule :C23H32FN5O2SiCouleur et forme :SolidMasse moléculaire :457.625EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formule :C49H32N12O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :884.99Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Degré de pureté :98%Couleur et forme :Odour SolidCDK-TCIP2
<p>DK-TCIP2 is an anticancer agent formed by linking the CDK9 inhibitor SNS-032 and the BCL6 inhibitor BI-3812. This compound exhibits anticancer activity both in vivo and in vitro, making it suitable for research in lymphoma.</p>Formule :C52H67ClN12O8S2Couleur et forme :SolidMasse moléculaire :1087.75CDK2/4-IN-1
<p>CDK2/4-IN-1 (compound B-4a) serves as both a CDK2/4 inhibitor and a microtubule polymerization inhibitor, making it useful in cancer research.</p>Couleur et forme :Odour SolidEGFR/CDK2-IN-4
<p>EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.</p>Formule :C24H16N6OS2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :468.55CDK6/9-IN-1
CAS :<p>CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).</p>Formule :C22H25ClN8OCouleur et forme :SolidMasse moléculaire :452.95CDK9-IN-26
<p>CDK9-IN-26, also known as compound 1, is a potent inhibitor of Cyclin-Dependent Kinase 9 (CDK9) with an IC50 value of 0.18 μM.[1]</p>Formule :C17H14N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :306.32BSJ-04-132
<p>Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.</p>Couleur et forme :Liquid(1S,3R,5R)-PIM447 dihydrochloride
<p>(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).</p>Formule :C24H25Cl2F3N4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :513.38WAY-322243
CAS :<p>WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.</p>Formule :C18H18N2O2SDegré de pureté :99.88%Couleur et forme :SoildMasse moléculaire :326.41PROTAC CDK9 degrader-5
CAS :<p>PROTAC CDK9 degrader-5 selectively degrades CDK9 isoforms 42, 55 with DC50 of 0.10μM, 0.14μM via proteasome.</p>Formule :C42H48Cl2N8O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :879.78CDK12-IN-2
CAS :<p>CDK12-IN-2 selectively inhibits CDK12 (IC50: 52 nM) with minimal effect on CDK2, CDK7, and CDK9, useful for CDK12 research.</p>Formule :C32H32N6O2Degré de pureté :99.31%Couleur et forme :SolidMasse moléculaire :532.64PROTAC CDK9 degrader 4
CAS :<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Formule :C43H56N10O5Couleur et forme :SolidMasse moléculaire :792.973MB-PP1
CAS :<p>3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor.</p>Formule :C17H21N5Degré de pureté :99.96%Couleur et forme :White SolidMasse moléculaire :295.38CDK7-IN-2 hydrochloride hydrate
CAS :<p>CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.</p>Formule :C26H42ClN7O4Couleur et forme :SolidMasse moléculaire :552.12CDK7/9-IN-1
CAS :<p>CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.</p>Formule :C24H32F3N5O2Couleur et forme :SolidMasse moléculaire :479.548Flavopiridol
CAS :<p>Flavopiridol (Alvocidib) blocks CDK1/2/4/6 by competing with ATP (IC50 ~40 nM); 7.5x selectivity over CDK7; also inhibits EGFR, PKA. In Phase 1/2 trials.</p>Formule :C21H20ClNO5Degré de pureté :97.74% - 99.86%Couleur et forme :SolidMasse moléculaire :401.84WAY-647802
CAS :<p>WAY-647802 is a CDK inhibitor.</p>Formule :C11H14N4O3Degré de pureté :99.53%Couleur et forme :SolidMasse moléculaire :250.25CDK-IN-12
CAS :<p>CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].</p>Formule :C26H29FN6OSCouleur et forme :SolidMasse moléculaire :492.61CGP-74514
CAS :<p>CGP-74514,CDK1 inhibitor (IC50=25 nM). Induces G2/M arrest, apoptosis. Used in bladder cancer research.</p>Formule :C19H24ClN7Degré de pureté :98.54%Couleur et forme :SoildMasse moléculaire :385.89CDK1-IN-2
CAS :<p>CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.</p>Formule :C17H11ClN2ODegré de pureté :98.53%Couleur et forme :SoildMasse moléculaire :294.73CDK5-IN-3
CAS :<p>CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA, and can be used in the study of cancer.</p>Formule :C22H26N4ODegré de pureté :98.21%Couleur et forme :SolidMasse moléculaire :362.47Palbociclib-d8
CAS :<p>Palbociclib-d8 (PD 0332991 D8) is the deuterated form of Palbociclib. Palbociclib is a CDK inhibitor that inhibits CDK4 and CDK6.</p>Formule :C24H21D8N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :455.58NCT02
CAS :<p>NCT02 degrades cyclin K, leading to CCNK and CDK12 degradation, potentially aiding metastatic CRC research.</p>Formule :C17H16N2O2SCouleur et forme :SolidMasse moléculaire :312.39TG003
CAS :<p>TG003 is a Clk1/Sty inhibitor that inhibits Clk1 and Clk4, suppresses cancer cell growth, and induces apoptosis.</p>Formule :C13H15NO2SDegré de pureté :99.46%Couleur et forme :SolidMasse moléculaire :249.33GP-82996
CAS :<p>GP-82996 (CINK4) inhibits CDK4/6; IC50s: 1.5 μM (CDK4/D1), 5.6 μM (CDK6/D1), 25 μM (Cdk5/p35); triggers U2OS cancer cell apoptosis.</p>Formule :C27H32N6ODegré de pureté :99.94%Couleur et forme :SolidMasse moléculaire :456.58(E/Z)-Zotiraciclib hydrochloride
CAS :<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent inhibitor of CDK2, JAK2, and FLT3.</p>Formule :C23H25ClN4OCouleur et forme :SolidMasse moléculaire :408.93LDC4297
CAS :<p>LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.</p>Formule :C23H28N8ODegré de pureté :98.25%Couleur et forme :SolidMasse moléculaire :432.52NU6102
CAS :<p>NU6102 is a CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.</p>Formule :C18H22N6O3SDegré de pureté :99.76%Couleur et forme :SolidMasse moléculaire :402.47Palbociclib hydrochloride
CAS :<p>Palbociclib hydrochloride is the salt form of Palbociclib, a selective and orally available CDK4 and CDK6 inhibitor for breast and hepatocellular carcinoma.</p>Formule :C24H31Cl2N7O2Degré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :520.46Ribociclib hydrochloride
CAS :<p>Ribociclib hydrochloride is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).</p>Formule :C23H31ClN8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :471FMF-04-159-2
CAS :<p>FMF-04-159-2 is a potent covalent CDK14 & CDK2 inhibito and is able to reduce α-Syn aggregation in neurons, and inhibits TNBC cancer progression.</p>Formule :C28H30Cl3N7O5SDegré de pureté :96.57%Couleur et forme :SolidMasse moléculaire :683.01Ribociclib-d6
CAS :<p>Ribociclib-d6 is a deuterated compound of Ribociclib (LEE011) for isotope tracing.Ribociclib is an orally available CDK4/6 inhibitor with antitumor activity.</p>Formule :C23H30N8OCouleur et forme :SolidMasse moléculaire :440.57CDK9-IN-1
CAS :<p>CDK9-IN-1 is a selective and potent CDK9 inhibitor with antiviral activity used in the study of PRRSV infections.</p>Formule :C26H21N5O4SDegré de pureté :98.52%Couleur et forme :SolidMasse moléculaire :499.54Dalpiciclib hydrochloride
<p>Dalpiciclib (SHR-6390) HCl is an oral CDK4/6 inhibitor with IC50s of 12.4/9.9 nM, an antitumor for breast and esophageal cancers.</p>Formule :C25H31ClN6O2Couleur et forme :SolidMasse moléculaire :483.01Atuveciclib
CAS :<p>Atuveciclib Racemate is an oral CDK9 inhibitor with a 13 nM IC50, targeting P-TEFb/CDK9 selectively.</p>Formule :C18H18FN5O2SDegré de pureté :98.8%Couleur et forme :SolidMasse moléculaire :387.43Avotaciclib trihydrochloride
CAS :<p>Avotaciclib trihydrochloride (BEY1107) is an oral CDK1 inhibitor targeting advanced pancreatic cancer.</p>Formule :C13H14Cl3N7ODegré de pureté :99%Couleur et forme :SolidMasse moléculaire :390.65DRB
CAS :<p>DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 μM)</p>Formule :C12H12Cl2N2O4Degré de pureté :99.46% - 99.83%Couleur et forme :White To Off-White Crystalline SolidMasse moléculaire :319.14Senexin A
CAS :<p>Senexin A is an effective and selective CDK8 inhibitor that also inhibits CDK19 with Kd values of 0.83 microns and 0.31 microns, respectively.</p>Formule :C17H14N4Degré de pureté :99.74%Couleur et forme :SolidMasse moléculaire :274.32LDC-4297 HCl (1453834-21-3(free base))
<p>LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM.</p>Formule :C23H29ClN8ODegré de pureté :100%Couleur et forme :SolidMasse moléculaire :469.02LY3143921
CAS :<p>LY3143921 ((S)-Example 2) is an orally active inhibitor of CDC7 kinase with broad in vitro anticancer activity [1].</p>Formule :C16H12FN5OCouleur et forme :SolidMasse moléculaire :309.3Cdk5 Substrate acetate
<p>Cdk5, a serine/threonine kinase active in neurons, phosphorylates proteins like histone H1; its synthetic substrate has a Km of 5 µM.</p>Formule :C55H103N15O14Degré de pureté :96.21%Couleur et forme :SolidMasse moléculaire :1198.5AMG 925 HCl
CAS :<p>AMG 925 HCl is a selective and potent dual inhibitor of FLT3 (IC50: 2±1 nM) and CDK4 (IC50: 3±1 nM).</p>Formule :C26H30ClN7O2Couleur et forme :SolidMasse moléculaire :508.02PF-06873600
CAS :<p>PF-06873600: oral CDK inhibitor (CDK2/4/6), Ki 0.09-0.16 nM, potential anticancer drug.</p>Formule :C20H27F2N5O4SDegré de pureté :98.77% - 99.55%Couleur et forme :SolidMasse moléculaire :471.52MLS-573151
CAS :<p>MLS-573151 is a selective inhibitor of GTPase Cdc42(EC50 of 2 μM).</p>Formule :C21H19N3O2SDegré de pureté :98.80%Couleur et forme :SolidMasse moléculaire :377.46CDK9-IN-30
CAS :<p>CDK9-IN-30 is one of the Tat peptide derivatives and inhibits HIV-1 long terminal repeat-activated transcription.</p>Formule :C16H20FNO3Degré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :293.33AZD-5438
CAS :<p>AZD-5438 is an effective inhibitor of CDK, for CDK1(IC50=16 nM), CDK2(IC50=6 nM), CDK9(IC50=20 nM).</p>Formule :C18H21N5O2SDegré de pureté :99.73% - 99.87%Couleur et forme :SolidMasse moléculaire :371.46Flavopiridol hydrochloride
CAS :<p>Flavopiridol hydrochloride (MDL 107826A), an inhibitor of cyclin-dependent kinase, is a synthetic N-methylpiperidinyl chlorophenyl flavone compound.</p>Formule :C21H21Cl2NO5Degré de pureté :98.87% - 99.88%Couleur et forme :SolidMasse moléculaire :438.3PHA-767491 hydrochloride
CAS :<p>PHA-767491 (CAY-10572) is a potent Cdc7/CDK9 inhibitor (IC50: 10/34 nM), selective against GSK3-β, CDK1/2, CDK5, MK2, CHK2, PLK1.</p>Formule :C12H12ClN3ODegré de pureté :99.56% - 99.92%Couleur et forme :SolidMasse moléculaire :249.69Seliciclib
CAS :<p>Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E, also inhibits Cdk7, Cdk5 and Cdc2. Seliciclib has antitumor effect. Cost-effective, quality assurance.</p>Formule :C19H26N6ODegré de pureté :97.15% - 99.89%Couleur et forme :White To Off-White SolidMasse moléculaire :354.45BSJ-03-123
CAS :<p>BSJ-03-123 is a potent, CDK6-selective small-molecule degrader.</p>Formule :C47H56N10O11Degré de pureté :97.78% - 99.38%Couleur et forme :SolidMasse moléculaire :937.01(E/Z)-Zotiraciclib
CAS :<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Formule :C23H24N4ODegré de pureté :97.75% - 99.92%Couleur et forme :SolidMasse moléculaire :372.46AG-494
CAS :<p>AG-494 (Tyrphostin B48) is an inhibitor of epidermal growth factor receptor kinase.</p>Formule :C16H12N2O3Degré de pureté :98.69%Couleur et forme :SolidMasse moléculaire :280.28Indirubin-3'-monoxime
CAS :<p>Indirubin-3'-monoxime (Indirubin-3'-oxime) is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100/180/250 nM for Cdk5/p35, Cdk1/</p>Formule :C16H11N3O2Degré de pureté :99.55%Couleur et forme :Dark Red SolidMasse moléculaire :277.28JSH-150
CAS :<p>JSH-150 is a highly selective CDK9 inhibitor(IC50 : 1 nM).</p>Formule :C24H33ClN6O2SDegré de pureté :99.96% - 99.96%Couleur et forme :SolidMasse moléculaire :505.08Dinaciclib
CAS :<p>Dinaciclib (SCH 727965) is a CDK inhibitor that selectively inhibits CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM).</p>Formule :C21H28N6O2Degré de pureté :98.21% - 99.75%Couleur et forme :SolidMasse moléculaire :396.49THZ1 Hydrochloride
<p>THZ1 Hydrochloride: selective covalent CDK7 inhibitor, IC50 of 3.2 nM; affects CDK12/13 & lowers MYC expression.</p>Formule :C31H29Cl2N7O2Couleur et forme :SolidMasse moléculaire :602.51PHA-767491
CAS :<p>PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.</p>Formule :C12H11N3ODegré de pureté :99.49% - >99.99%Couleur et forme :SolidMasse moléculaire :213.24THZ1
CAS :<p>THZ1 (CDK7 inhibitor) is a selective inhibitor of CDK7, binding to the Cys residue located at the outer end of the classical kinase domain. Cost-effective and quality-assured.</p>Formule :C31H28ClN7O2Degré de pureté :95.09% - 99.27%Couleur et forme :SolidMasse moléculaire :566.05Bromosporine
CAS :<p>Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.</p>Formule :C17H20N6O4SDegré de pureté :99.65% - 99.79%Couleur et forme :SolidMasse moléculaire :404.447BIO
CAS :<p>7BIO triggers nonapoptotic death, blocks FLT3, DYRK1A/2, Aurora B/C kinases.</p>Formule :C16H10BrN3O2Degré de pureté :99.67%Couleur et forme :SolidMasse moléculaire :356.17Briciclib
CAS :<p>Briciclib (ON 014185) is a small molecule that suppresses cyclin D1 accumulation in Y cells.</p>Formule :C19H23O10PSDegré de pureté :98% - 99.84%Couleur et forme :SolidMasse moléculaire :474.42BS-181 dihydrochloride
CAS :<p>BS-181 dihydrochloride: Potent CDK7 inhibitor (IC50: 21 nM), less effective on CDK2/5/9, no impact on CDK1/4/6, halts cancer cell growth, triggers apoptosis.</p>Formule :C22H34Cl2N6Couleur et forme :SolidMasse moléculaire :453.462-Chloropyrazine
CAS :<p>2-Chloropyrazine is used in chemical industry.</p>Formule :C4H3ClN2Degré de pureté :98.98% - 99.89%Couleur et forme :Clear Colorless To Yellowish LiquidMasse moléculaire :114.53(E/Z)-Zotiraciclib citrate
<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) citrate is a potent inhibitor of CDK2, JAK2 and FLT3 and can be used in cancer research.</p>Formule :C29H32N4O8Couleur et forme :SolidMasse moléculaire :564.59ON-013100
CAS :<p>ON-013100 is an antineoplastic drug. ON-013100 also acts as a mitotic inhibitor that could inhibit Cyclin D1 expression.</p>Formule :C19H22O7SDegré de pureté :98.27%Couleur et forme :SolidMasse moléculaire :394.44FIT-039
CAS :<p>FIT-039 is a selective and ATP-competitive, orally active inhibitor of CDK9( IC50 : 5.8 μM;CDK9/cyclin T1).</p>Formule :C17H18FN3SDegré de pureté :98.61%Couleur et forme :SolidMasse moléculaire :315.41RGB-286638 free base
CAS :<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Formule :C29H35N7O4Degré de pureté :98% - 99.91%Couleur et forme :SolidMasse moléculaire :545.63BMS-265246
CAS :<p>BMS-265246 is a potent and selective CDK1/2 inhibitor.</p>Formule :C18H17F2N3O2Degré de pureté :99.25% - 99.57%Couleur et forme :SolidMasse moléculaire :345.34SR-4835
CAS :<p>SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM), which disables triple-negative breast cancer (</p>Formule :C21H20Cl2N10ODegré de pureté :98.09% - >99.99%Couleur et forme :SolidMasse moléculaire :499.36KB-0742 dihydrochloride
CAS :<p>KB-0742 dihydrochloride is a potent, selective and orally inhibitor of CDK9.</p>Formule :C16H27Cl2N5Degré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :360.33LY3405105
CAS :<p>LY3405105 (1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-</p>Formule :C26H39N7O3Degré de pureté :99.66%Couleur et forme :SolidMasse moléculaire :497.63HQ461
CAS :<p>HQ461, a molecular glue, boosts CDK12-DDB1 binding, lowers cyclin K, impedes CDK12 phosphorylation, hinders DNA repair genes, and induces cell death.</p>Formule :C15H15N5OS2Degré de pureté :98.11%Couleur et forme :SolidMasse moléculaire :345.44AT7519 Hydrochloride
CAS :<p>AT7519 Hydrochloride (AT7519 HCl) is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9.</p>Formule :C16H18Cl3N5O2Degré de pureté :99.66% - 99.9%Couleur et forme :SolidMasse moléculaire :418.71Fadraciclib
CAS :<p>Fadraciclib (CYC065) is an orally available, second-generation ATP-competitive inhibitor of CDK2/CDK9 kinases (IC50s: 5/26 nM).</p>Formule :C21H31N7ODegré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :397.52Cucurbitacin E
CAS :<p>Cucurbitacin E, from Cucumic melo, inhibits cyclin B1/CDC2, and has neuroprotective, anti-proliferative, anti-cancer, and pain relief properties.</p>Formule :C32H44O8Degré de pureté :98.88% - 99.87%Couleur et forme :SolidMasse moléculaire :556.69MSC2530818
CAS :<p>MSC2530818 is an effective, selective and orally available CDK8 inhibitor (IC50: 2.6 nM).</p>Formule :C18H17ClN4ODegré de pureté :98.93%Couleur et forme :SolidMasse moléculaire :340.81CKI-7
CAS :<p>CKI-7 is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor.</p>Formule :C11H14Cl3N3O2SDegré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :358.67Amantadine
CAS :<p>Amantadine (1-Aminoadamantane), an antiviral, is a weak antagonist of the NMDA-type glutamate receptor, increases dopamine release and blocks dopamine reuptake.</p>Formule :C10H17NDegré de pureté :99.73% - 99.94%Couleur et forme :Hexakistetrahedral Crystals By Sublimation SolidMasse moléculaire :151.25Abemaciclib methanesulfonate
CAS :<p>Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).</p>Formule :C27H32F2N8·CH4O3SDegré de pureté :98.69% - 99.44%Couleur et forme :SolidMasse moléculaire :602.7Desmethylglycitein
CAS :<p>Desmethylglycitein (6,7,4'-Trihydroxyisoflavone) , is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1, which has</p>Formule :C15H10O5Degré de pureté :97.93%Couleur et forme :SolidMasse moléculaire :270.24LY3177833
CAS :<p>LY3177833 is an Cdc7 kinase inhibitor (IC50 : 3.3 nM)</p>Formule :C16H12FN5ODegré de pureté :99.87%Couleur et forme :SolidMasse moléculaire :309.3SCH900776 (S-isomer)
CAS :<p>SCH900776 S-isomer (MK-8776 S-isomer) is an effective, specific and orally bioavailable inhibitor of checkpoint kinase Chk1 (IC50: 3 nM).</p>Formule :C15H18BrN7Degré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :376.25Dalpiciclib
CAS :<p>Dalpiciclib (SHR-6390) selectively inhibits CDK4/6 (IC50: 12.4/9.9 nM), is orally available, and impedes esophageal cancer growth.</p>Formule :C25H30N6O2Degré de pureté :99.69%Couleur et forme :SolidMasse moléculaire :446.54BUR1
CAS :<p>BUR1 is a Saccharomyces cerevisiae cyclin-dependent kinase (CDK) and is homologous to mammalian Cdk9, which functions in transcriptional elongation.</p>Formule :C16H17N5Degré de pureté :90%Couleur et forme :SolidMasse moléculaire :279.34SNS-032
CAS :<p>SNS-032 (BMS-387032) is a selective inhibitor of CDK2 and is 10- and 20-fold selective over CDK1/CDK4. SNS-032 is sensitive to CDK7/9, and no effect on CDK6.</p>Formule :C17H24N4O2S2Degré de pureté :98.27% - 99.91%Couleur et forme :SolidMasse moléculaire :380.53CC-671
CAS :<p>CC-671 is a dual TTK protein kinase (IC50: 0.005 μM) /CLK2 (IC50: 0.006 μM) inhibitor.</p>Formule :C28H28N6O4Degré de pureté :98.66% - 98.8%Couleur et forme :SolidMasse moléculaire :512.56NVP-LCQ195
CAS :<p>NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).</p>Formule :C17H19Cl2N5O4SDegré de pureté :99.56% - 99.85%Couleur et forme :SolidMasse moléculaire :460.33Aminopurvalanol A
CAS :<p>Aminopurvalanol A is a competitive, selective and cell-permeable inhibitor of cyclin-dependent kinase (CDK) that potently inhibits Cyclin A/cdk2, Cyclin B/cdk1</p>Formule :C19H26ClN7ODegré de pureté :99.73%Couleur et forme :SolidMasse moléculaire :403.91
![[Ala92]-p16 (84-103)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP2133.webp&w=3840&q=75)
![[pThr3]-CDK5 Substrate](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1602.webp&w=3840&q=75)
